## NDAQ: Nasdaq, Inc. - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 1.47 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($89.77)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Annual Changes to the Nasdaq-100 Index®**
- Source: The Globe and Mail | 20251213T015952 | Neutral | Relevance: 81%
- Nasdaq announced the annual reconstitution of the Nasdaq-100 Index®, effective December 22, 2025. Six companies will be added, including Alnylam Pharmaceuticals and Western Digital Corp., while six others, such as Biogen Inc. and Lululemon Athletica Inc., will be removed. The Nasdaq-100 Index tracks 100 of the largest non-financial companies on the Nasdaq Stock Market and underpins over 200 tracking products with more than $600 billion in assets under management.

**2. B. Riley (RILY.US) Submits 10-Q Filing to Nasdaq in Effort to Maintain Listing After Facing Delisting Risks**
- Source: 富途牛牛 | 20251216T070925 | Neutral | Relevance: 72%
- B. Riley Financial Inc. (RILY.US) has submitted its overdue second-quarter report (10-Q) to the SEC, a critical step towards meeting Nasdaq's listing requirements and avoiding delisting. This filing disclosed a profit for the quarter, significantly improving from a loss in the previous year, and the company is working to submit its third-quarter report before the January 20 deadline. The move comes after the company faced financial reporting deficiencies, investment losses, and an ongoing civil investigation, which led to repeated delisting threats from Nasdaq.

**3. NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE**
- Source: Financial Times | 20251215T135719 | Somewhat-Bullish | Relevance: 71%
- The NYSE provides a daily pre-market update, noting that stocks are fractionally higher to start a busy economic data week. Seven of the top 10 IPOs in 2025 debuted on the NYSE, and NYSE President Lynn Martin highlighted maintaining momentum and simplifying the path for companies to go public as a 2026 priority. Baron Capital launched new active ETFs, and Dr. Martin Makary discussed modernizing FDA processes for drug development.

**4. CME Group Inc. Stock (NASDAQ: CME) This Week: Shares Rebound on Strong Volume Data, SEC Clearing-House Greenlight — Week Ahead Outlook (Updated Dec. 12, 2025)**
- Source: ts2.tech | 20251213T010903 | Somewhat-Bullish | Relevance: 64%
- CME Group Inc. (NASDAQ: CME) shares rebounded this week, closing at $273.55, driven by a surge in November trading activity which saw a 10% year-over-year increase in average daily volume and record crypto participation. The SEC also approved CME's new securities clearing house, CME Securities Clearing Inc., vital for forthcoming U.S. Treasury and repo clearing mandates. With significant U.S. economic data releases expected next week, CME's core franchises in rates and equity indexes could see increased volatility and trading volumes.

**5. General American Investors Announces Issue Price for the 2025 Year-End Dividend and Distribution Payable on December 26, 2025**
- Source: Stock Titan | 20251213T040852 | Neutral | Relevance: 64%
- General American Investors Company, Inc. (NYSE: GAM) announced an issue price of $58.745 per share for its 2025 year-end dividend and distribution, payable on December 26, 2025, to stockholders who elected to receive additional shares. The total dividend and distribution amounts to $6.40 per share, consisting of $5.95 from capital gains and $0.45 from net investment income. The issue price was determined by the average high and low prices on the NYSE on December 12, 2025, which was below the net asset value of $65.40 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Barclays | $114 | $109 | +5% |
| 2025-11-20 | Morgan Stanley | $110 | $97 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Barclays | main | Overweight |
| 2025-11-20 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($2.76M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+6.9%)
- Investor AB: 10.2% (0.0%)
- Blackrock Inc.: 7.0% (+8.3%)
- Wellington Managemen: 7.0% (-3.5%)
- Massachusetts Financ: 4.6% (-3.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 24.3x stretched relative to 11% growth. Quality metrics strong (margin 20%). Analyst sentiment positive (2 raises, avg +9%). Insider selling cluster ($2.8M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $53.3B |
| Beta | 1.02 |
| 52W Range | $64.84 - $97.63 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 24.3 |
| Current P/E | 27.1 |
| YoY Growth | 11.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.7% to 4.3% (+3.7% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 70th percentile. MRS_5 at 1.9% confirms short-term momentum alignment. AM_20 at 4.0% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.31% (CS: 71) | Strong |
| RSI_14 | 64.1 | Neutral |
| MACD Histogram | 0.49 | Bullish |
| vs SMA20 | 1.038x | Above |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 1.083x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $92.93
- **Stop Loss:** $89.77 (3.4% risk)
- **Target:** $99.25 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 379
- **Position Value:** $35,220.47
- **Portfolio %:** 35.22%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-28 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.88 | +3.7% |
| 2025Q2 | $0.81 | $0.85 | +4.6% |
| 2025Q1 | $0.77 | $0.79 | +2.5% |
| 2024Q4 | $0.75 | $0.76 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*